Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

$616.48

-2.09 (-0.34%)

(As of 11:09 AM ET)

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
4

Buy
17

Based on 21 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 4 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for TMO.

Consensus Price Target

$652.06
5.70% Upside

According to the 21 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $652.06. The highest price target for TMO is $767.00, while the lowest price target for TMO is $575.00. The average price target represents a forecasted upside of 5.70% from the current price of $616.48.

Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

TMO Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$652.06	$630.41	$606.47	$627.13
Forecasted Upside	5.70% Upside	2.49% Upside	13.24% Upside	26.48% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Revolutionary Tech Alert: How Elon Musk is Changing Lives (Ad)

"Elon Musk's Neuralink just received FDA breakthrough status for a revolutionary device designed to restore vision to those who've lost it entirely. And the first human clinical trials have opened for recruitment.

Click here to see it.

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Thermo Fisher Scientific Stock vs. The Competition

Type	Thermo Fisher Scientific	Medical Companies	S&P 500
Consensus Rating Score	2.85	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	5.15% Upside	823.01% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent TMO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	Stephens 4 of 5 stars		Initiated Coverage	Overweight	$680.00	+9.93%
9/20/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Buy ➝ Buy	$615.00 ➝ $680.00	+10.76%
9/20/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$650.00 ➝ $670.00	+9.13%
9/20/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$655.00 ➝ $680.00	+10.95%
9/20/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$767.00 ➝ $767.00	+25.14%
9/16/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
Get the Latest News and Ratings for TMO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors with MarketBeat's FREE daily newsletter.
9/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$600.00 ➝ $675.00	+10.44%
8/27/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$670.00	+9.76%
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$648.00 ➝ $658.00	+10.32%
7/25/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$650.00 ➝ $660.00	+9.56%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$620.00 ➝ $632.00	+9.95%
7/2/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$615.00 ➝ $600.00	+11.45%
6/28/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$615.00 ➝ $600.00	+8.49%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Buy	$600.00 ➝ $650.00	+14.44%
4/30/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$660.00 ➝ $670.00	+17.13%
4/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$600.00 ➝ $610.00	+6.54%
4/10/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$550.00 ➝ $640.00	+10.94%
3/18/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$620.00	+6.70%
1/8/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$575.00	+15.58%
10/26/2023	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Sector Weight
7/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$620.00	+17.89%
2/2/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$620.00 ➝ $630.00	+7.26%
2/2/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$690.00 ➝ $711.00	+21.05%
10/27/2022	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:35 AM ET.

Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 29, 2024. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

Thermo Fisher Scientific Inc. provides a wide range of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products, offering diversified revenue streams and potential for growth.
Recent institutional investments in Thermo Fisher Scientific Inc., such as Capital World Investors acquiring additional shares, indicate confidence in the company's future performance and growth prospects.
The company's stock price has shown stability and growth, with recent transactions indicating strong investor interest and positive market sentiment.
Thermo Fisher Scientific Inc. has a strong presence in multiple global markets, including North America, Europe, and Asia-Pacific, providing geographic diversification and exposure to different economic conditions.
With a significant percentage of the company's stock owned by institutional investors and hedge funds, Thermo Fisher Scientific Inc. may benefit from strategic long-term investment strategies and stability in shareholder base.

Thermo Fisher Scientific
Bear Case

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

Thermo Fisher Scientific Inc. faces potential risks associated with changes in regulatory environments, market competition, and technological advancements that could impact its product offerings and market position.
While recent insider selling activities may not always indicate negative prospects, investors should carefully monitor insider transactions for any potential signals about the company's future performance.
The company's high institutional ownership percentage may lead to limited influence for individual retail investors in decision-making processes and corporate governance matters.
Investors should consider the impact of macroeconomic factors, such as global trade tensions or economic downturns, on Thermo Fisher Scientific Inc.'s business operations and financial performance.
Market volatility and fluctuations in the life sciences and biopharma sectors could affect Thermo Fisher Scientific Inc.'s stock price and overall investment returns, requiring a long-term perspective and risk management strategies.

TMO Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $652.06, with a high forecast of $767.00 and a low forecast of $575.00.
: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last year. There are currently 4 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMO shares.
: According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 5.77% based on their 12-month stock forecasts.
: Over the previous 90 days, Thermo Fisher Scientific's stock had 1 upgrade by analysts.
: Thermo Fisher Scientific has been rated by research analysts at Bank of America, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Robert W. Baird, Royal Bank of Canada, Stephens, Stifel Nicolaus, TD Cowen, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Thermo Fisher Scientific more than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.86 while the average consensus rating score for "medical" companies is 2.78. Learn more on how TMO compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Solar Energy: What Donald Trump, Elon Musk, and the DNC All Agree On (Ad)

Find out how one NASDAQ-listed company is poised to tackle the home energy crisis, bringing a unique solution to soaring costs - one that's already being delivered to thousands of homes across North America... And sought after by some of the world's most valuable companies, including Fortune 100-listed Honeywell International.

GET THE FULL REPORT NOW

This page (NYSE:TMO) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners